Nanoparticle drug delivery systems for synergistic delivery of tumor therapy.
co-delivery
combination therapy
nanoparticles
synergistic action
tumor therapy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
11
2022
accepted:
02
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Nanoparticle drug delivery systems have proved anti-tumor effects; however, they are not widely used in tumor therapy due to insufficient ability to target specific sites, multidrug resistance to anti-tumor drugs, and the high toxicity of the drugs. With the development of RNAi technology, nucleic acids have been delivered to target sites to replace or correct defective genes or knock down specific genes. Also, synergistic therapeutic effects can be achieved for combined drug delivery, which is more effective for overcoming multidrug resistance of cancer cells. These combination therapies achieve better therapeutic effects than delivering nucleic acids or chemotherapeutic drugs alone, so the scope of combined drug delivery has also been expanded to three aspects: drug-drug, drug-gene, and gene-gene. This review summarizes the recent advances of nanocarriers to co-delivery agents, including i) the characterization and preparation of nanocarriers, such as lipid-based nanocarriers, polymer nanocarriers, and inorganic delivery carriers; ii) the advantages and disadvantages of synergistic delivery approaches; iii) the effectual delivery cases that are applied in the synergistic delivery systems; and iv) future perspectives in the design of nanoparticle drug delivery systems to co-deliver therapeutic agents.
Identifiants
pubmed: 36874010
doi: 10.3389/fphar.2023.1111991
pii: 1111991
pmc: PMC9978018
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1111991Informations de copyright
Copyright © 2023 Chen, Liu, Lu and Tian.
Déclaration de conflit d'intérêts
Author XL was employed by Shandong Boan Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomaterials. 2017 Feb;117:54-65
pubmed: 27936417
Int J Nanomedicine. 2017 Jan 31;12:955-968
pubmed: 28203075
Int J Nanomedicine. 2012;7:2473-81
pubmed: 22701315
J Control Release. 2017 Oct 28;264:306-332
pubmed: 28844756
Eur J Pharm Biopharm. 2005 Jul;60(2):247-66
pubmed: 15939236
J Control Release. 2014 Nov 28;194:228-37
pubmed: 25220161
ACS Appl Mater Interfaces. 2020 Apr 1;12(13):14770-14783
pubmed: 32149497
Chem Rec. 2020 Dec;20(12):1474-1504
pubmed: 32970383
J Exp Clin Cancer Res. 2018 Nov 1;37(1):266
pubmed: 30382874
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
Biomaterials. 2013 Sep;34(29):7204-14
pubmed: 23800742
Acta Biomater. 2021 Oct 15;134:649-663
pubmed: 34289420
Polymers (Basel). 2022 Apr 28;14(9):
pubmed: 35566982
Cancer Res. 2006 May 1;66(9):4863-71
pubmed: 16651442
J Nanobiotechnology. 2019 Mar 27;17(1):44
pubmed: 30917812
J Control Release. 2015 Dec 28;220(Pt A):160-168
pubmed: 26497930
Toxics. 2018 Jun 26;6(3):
pubmed: 29949888
Nat Rev Drug Discov. 2011 Oct 21;10(11):835-52
pubmed: 22015921
Biomed Pharmacother. 2016 Dec;84:954-961
pubmed: 27764758
Expert Opin Drug Deliv. 2019 Jan;16(1):69-78
pubmed: 30496697
Biomater Sci. 2022 May 31;10(11):2865-2876
pubmed: 35445677
J Biosci. 2019 Sep;44(4):
pubmed: 31502562
Adv Funct Mater. 2021 Jan 27;31(5):
pubmed: 34366761
Drug Deliv. 2020 Dec;27(1):1397-1411
pubmed: 33096948
Oncotarget. 2015 Dec 8;6(39):42150-68
pubmed: 26517524
ACS Nano. 2015;9(4):3540-57
pubmed: 25776964
Small. 2010 Sep 20;6(18):1952-67
pubmed: 20690133
Expert Opin Drug Deliv. 2017 Jan;14(1):75-92
pubmed: 27339650
Asian J Pharm Sci. 2019 Jan;14(1):78-85
pubmed: 32104440
Nat Commun. 2022 Jul 25;13(1):4282
pubmed: 35879315
Int J Biol Macromol. 2022 Mar 1;200:335-349
pubmed: 34999039
J Am Chem Soc. 2014 Apr 9;136(14):5181-4
pubmed: 24669930
Nanomedicine (Lond). 2019 Aug;14(15):2083-2100
pubmed: 31368405
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41118-41128
pubmed: 30444340
Biomaterials. 2011 Jul;32(21):4914-24
pubmed: 21489622
Angew Chem Int Ed Engl. 2014 Nov 10;53(46):12320-64
pubmed: 25294565
Eur J Pharm Biopharm. 2014 Jan;86(1):7-22
pubmed: 24007657
Drug Deliv. 2022 Dec;29(1):192-202
pubmed: 34984953
Biotechnol Adv. 2019 Sep - Oct;37(5):801-825
pubmed: 31034960
Nanomedicine. 2017 Nov;13(8):2507-2516
pubmed: 28577837
Expert Opin Pharmacother. 2013 Aug;14(11):1545-58
pubmed: 23683110
Int J Pharm. 2019 Apr 5;560:126-135
pubmed: 30742982
J Agric Food Chem. 2008 Jun 25;56(12):4813-8
pubmed: 18522405
Eur J Pharm Biopharm. 2014 May;87(1):1-18
pubmed: 24530885
J Control Release. 2021 Jul 10;335:437-448
pubmed: 34081996
Adv Colloid Interface Sci. 2021 Aug;294:102483
pubmed: 34274723
Theranostics. 2021 Jan 1;11(5):2442-2459
pubmed: 33500735
Pharm Nanotechnol. 2019;7(1):3-23
pubmed: 30666921
Nat Rev Drug Discov. 2010 Mar;9(3):215-36
pubmed: 20190787
Front Immunol. 2018 Apr 18;9:783
pubmed: 29720976
J Control Release. 2015 Dec 28;220(Pt B):631-41
pubmed: 26307351
Int J Pharm. 2021 Jan 5;592:120033
pubmed: 33144189
J Mater Chem B. 2015 Oct 21;3(39):7724-7733
pubmed: 26617985
Theranostics. 2021 Mar 13;11(11):5464-5490
pubmed: 33859758
Sci Rep. 2018 May 14;8(1):7498
pubmed: 29760419
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Biomaterials. 2015 Aug;61:10-25
pubmed: 25996409
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Pharm Res. 2017 Dec;34(12):2829-2841
pubmed: 28948461
Acta Pharm Sin B. 2022 Oct;12(10):3822-3842
pubmed: 36213541
Biomaterials. 2021 Aug;275:120907
pubmed: 34090050
Nanoscale. 2021 Mar 12;13(9):4887-4898
pubmed: 33625408
Adv Drug Deliv Rev. 2020;154-155:64-78
pubmed: 32768564
Acta Biomater. 2019 Dec;100:365-377
pubmed: 31586724
Drug Deliv. 2016 Nov;24(1):792-799
pubmed: 28494629
Mol Ther. 2010 Sep;18(9):1650-6
pubmed: 20606648
Int J Pharm. 2021 Mar 1;596:120291
pubmed: 33524527
Acta Pharm Sin B. 2018 Mar;8(2):165-177
pubmed: 29719777
J Urol. 2015 Jul;194(1):230-7
pubmed: 25681288
BMB Rep. 2019 Jul;52(7):415-423
pubmed: 31186087
Nanomedicine. 2015 Feb;11(2):313-27
pubmed: 25461284
Int J Mol Sci. 2013 Nov 05;14(11):21899-942
pubmed: 24196356
J Liposome Res. 2005;15(3-4):141-55
pubmed: 16393906
Chem Rev. 2021 Oct 27;121(20):12181-12277
pubmed: 34279087
Nanomedicine. 2017 Jul;13(5):1703-1713
pubmed: 28343014
Molecules. 2020 Sep 16;25(18):
pubmed: 32947799
J Biomater Sci Polym Ed. 2015;26(18):1343-56
pubmed: 26381379
Eur J Pharm Biopharm. 2020 Nov;156:84-96
pubmed: 32882423
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Pharmaceutics. 2021 Nov 30;13(12):
pubmed: 34959323
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Biomed Res Int. 2014;2014:646787
pubmed: 25143941
Int J Biol Macromol. 2022 Apr 15;204:576-586
pubmed: 35157902
ACS Biomater Sci Eng. 2022 May 9;8(5):1907-1920
pubmed: 35482571
Int J Cancer. 2018 Feb 1;142(3):597-606
pubmed: 28960310
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79
pubmed: 24120656
Biomed Pharmacother. 2019 Jan;109:1728-1739
pubmed: 30551427
Mol Biosyst. 2012 Oct 30;8(12):3288-94
pubmed: 23086311
Int J Nanomedicine. 2018 Mar 15;13:1569-1583
pubmed: 29588585
Cell Biol Int. 2013 May;37(5):415-9
pubmed: 23504853
Pharmaceutics. 2021 Apr 09;13(4):
pubmed: 33918635
Curr Drug Metab. 2019;20(6):416-429
pubmed: 30227814
Adv Drug Deliv Rev. 2021 Sep;176:113851
pubmed: 34224787
Int J Nanomedicine. 2019 Apr 02;14:2233-2251
pubmed: 31118604
Biomed Pharmacother. 2016 Oct;83:1428-1435
pubmed: 27592131
Int J Pharm. 2014 Oct 20;474(1-2):112-22
pubmed: 25138252
Hum Gene Ther. 2019 Dec;30(12):1531-1546
pubmed: 31547718
Pharmaceutics. 2020 May 07;12(5):
pubmed: 32392811
Int J Mol Sci. 2018 Jul 06;19(7):
pubmed: 29986450
Methods Mol Biol. 2010;629:141-58
pubmed: 20387148
Stem Cells Int. 2016;2016:2087204
pubmed: 27200096
Cancer Drug Resist. 2021 Mar 19;4(1):44-68
pubmed: 35582007
J Drug Target. 2019 Aug;27(7):797-805
pubmed: 30481072
Pharm Res. 2019 Aug 8;36(10):145
pubmed: 31396764
Curr Top Med Chem. 2019;19(6):394-412
pubmed: 30834839
Theranostics. 2015 Apr 20;5(8):818-33
pubmed: 26000055
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 28941203
ACS Appl Bio Mater. 2021 Sep 20;4(9):7168-7175
pubmed: 35006948
Drug Deliv. 2022 Dec;29(1):574-587
pubmed: 35156491
Ultrasound Med Biol. 2017 Jan;43(1):69-82
pubmed: 27751594
Curr Pharm Des. 2020;26(34):4272-4276
pubmed: 32693760
Oncol Res Treat. 2020;43(6):299-306
pubmed: 32380503
Biomater Sci. 2015 Jan;3(1):163-74
pubmed: 26214199
Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111664
pubmed: 33545830
Angew Chem Int Ed Engl. 2003;42(47):5796-800
pubmed: 14673909
Mater Sci Eng C Mater Biol Appl. 2017 Jan 1;70(Pt 1):418-429
pubmed: 27770912
Int J Nanomedicine. 2012;7:4269-83
pubmed: 22904633
Drug Discov Today. 2005 Feb 15;10(4):267-73
pubmed: 15708745
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Integr Biol (Camb). 2013 Jan;5(1):19-28
pubmed: 23042147
Front Immunol. 2015 May 06;6:201
pubmed: 25999946
J Med Chem. 2018 Jun 28;61(12):5108-5121
pubmed: 29251920
Bioact Mater. 2020 Dec 13;6(7):1878-1909
pubmed: 33364529
Einstein (Sao Paulo). 2017 Jul-Sep;15(3):369-375
pubmed: 29091160
Acta Biomater. 2018 Aug;76:257-274
pubmed: 29960010
Annu Rev Med. 2012;63:185-98
pubmed: 21888516
Adv Healthc Mater. 2014 Aug;3(8):1250-60
pubmed: 24623647
J Healthc Eng. 2019 Apr 2;2019:9156921
pubmed: 31065331
Adv Drug Deliv Rev. 2019 Apr;144:133-147
pubmed: 31102606
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
Mol Cell Biochem. 2020 Nov;474(1-2):73-81
pubmed: 32696132
J Pharm Pharm Sci. 2011;14(1):67-77
pubmed: 21501554
Expert Opin Drug Deliv. 2015;12(10):1649-60
pubmed: 26005036
Int J Nanomedicine. 2015 Feb 11;10:1223-33
pubmed: 25709444
Nanomaterials (Basel). 2020 Dec 09;10(12):
pubmed: 33317099
ACS Appl Mater Interfaces. 2013 Aug 28;5(16):7995-8001
pubmed: 23869943
Colloids Surf B Biointerfaces. 2014 Nov 1;123:498-505
pubmed: 25315499
Curr Drug Targets. 2020;21(15):1613-1624
pubmed: 32651965
Adv Drug Deliv Rev. 2020;154-155:37-63
pubmed: 32526452
Biochem Biophys Res Commun. 2021 May 14;553:191-197
pubmed: 33774221
Mol Cancer. 2020 Sep 24;19(1):145
pubmed: 32972405
Asian Pac J Cancer Prev. 2014;15(2):517-35
pubmed: 24568455
Drug Deliv. 2017 Nov;24(1):1909-1926
pubmed: 29191057
Biomaterials. 2014 Mar;35(10):3331-9
pubmed: 24456604
Mater Sci Eng C Mater Biol Appl. 2018 Nov 1;92:1041-1060
pubmed: 30184728
J Mater Chem B. 2017 Sep 14;5(34):7082-7098
pubmed: 32263899
J Nanobiotechnology. 2021 Sep 27;19(1):290
pubmed: 34579711
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Adv Pharm Bull. 2021 May;11(3):426-438
pubmed: 34513617
Theranostics. 2019 Jan 25;9(3):837-852
pubmed: 30809312
Nanomaterials (Basel). 2019 Apr 19;9(4):
pubmed: 31010180
Pharm Nanotechnol. 2019;7(2):90-112
pubmed: 30907329
Pharmaceutics. 2022 Jul 15;14(7):
pubmed: 35890364
Adv Drug Deliv Rev. 2020;154-155:102-122
pubmed: 32650041
Mol Pharm. 2017 May 1;14(5):1429-1438
pubmed: 28195491
J Liposome Res. 2022 Sep;32(3):265-275
pubmed: 34904521
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:954-964
pubmed: 27987794
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:1327-1341
pubmed: 27987688
Biomaterials. 2015 Dec;72:74-89
pubmed: 26344365
Adv Drug Deliv Rev. 2010 Jan 31;62(1):12-27
pubmed: 19796660
Expert Opin Drug Deliv. 2019 Nov;16(11):1205-1226
pubmed: 31530041
J Nanobiotechnology. 2022 Apr 2;20(1):177
pubmed: 35366888
Med Res Rev. 2021 Jan;41(1):525-555
pubmed: 33047304
J Biomater Sci Polym Ed. 2015;26(13):813-27
pubmed: 26166244
J Control Release. 2016 Dec 28;244(Pt A):108-121
pubmed: 27871992
Acta Biomater. 2015 Jan;11:393-403
pubmed: 25246314
Pharm Dev Technol. 2022 Sep;27(7):785-793
pubmed: 36043390
Drug Deliv. 2016 Nov;23(9):3665-3673
pubmed: 27749102
Hematol Oncol Clin North Am. 2017 Oct;31(5):753-770
pubmed: 28895845
Int J Mol Sci. 2020 Jan 12;21(2):
pubmed: 31940963
Blood. 1965 Nov;26(5):642-56
pubmed: 5321112
J Drug Target. 2011 Dec;19(10):900-14
pubmed: 21981718
ACS Appl Mater Interfaces. 2020 Jan 29;12(4):4308-4322
pubmed: 31939276
Prog Biomater. 2019 Sep;8(3):155-168
pubmed: 31197663
Cancer Lett. 2014 Sep 28;352(1):66-80
pubmed: 24139965
Drug Des Devel Ther. 2022 Aug 11;16:2683-2693
pubmed: 35983428
Int J Pharm. 2017 Nov 25;533(1):111-124
pubmed: 28947245
Int J Nanomedicine. 2012;7:999-1013
pubmed: 22403484
Ther Deliv. 2016;7(4):245-55
pubmed: 27010986
Eur J Pharm Biopharm. 2012 Feb;80(2):268-73
pubmed: 22108492
Nanoscale. 2012 Nov 21;4(22):7185-93
pubmed: 23070403
Heliyon. 2022 May 13;8(5):e09403
pubmed: 35663739
Nanomaterials (Basel). 2020 Oct 05;10(10):
pubmed: 33027891
Drug Deliv. 2016 May;23(4):1398-403
pubmed: 26079530
Nature. 2012 Jul 26;487(7408):505-9
pubmed: 22763448
Int J Nanomedicine. 2021 Nov 30;16:7847-7857
pubmed: 34876813
Cancer Discov. 2013 Apr;3(4):406-17
pubmed: 23358650
Pharmaceutics. 2021 Oct 09;13(10):
pubmed: 34683943
J Control Release. 2013 Nov 28;172(1):207-218
pubmed: 23965281
Pharmaceutics. 2019 Sep 03;11(9):
pubmed: 31484456
Int J Nanomedicine. 2017 Aug 16;12:5879-5892
pubmed: 28860754
J Hematol Oncol. 2019 Dec 17;12(1):137
pubmed: 31847897
J Control Release. 2016 May 10;229:80-92
pubmed: 26945977
Mater Sci Eng C Mater Biol Appl. 2020 May;110:110698
pubmed: 32204012
Theranostics. 2021 Apr 19;11(13):6370-6392
pubmed: 33995663
NAR Cancer. 2020 Aug 11;2(3):zcaa016
pubmed: 34316688
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jan;393(1):1-11
pubmed: 31372697
Int J Pharm. 2017 Jun 20;525(2):407-417
pubmed: 28373100
Curr Pharm Des. 2021;27(43):4416-4432
pubmed: 34348615
ACS Nano. 2022 Aug 23;16(8):13168-13182
pubmed: 35920660
Int J Biol Macromol. 2019 Mar 1;124:1299-1311
pubmed: 30248424
Macromol Rapid Commun. 2020 Sep;41(18):e2000298
pubmed: 32686228
Sci Rep. 2016 Aug 26;6:32363
pubmed: 27562435
Eur J Pharm Biopharm. 2022 Oct;179:156-165
pubmed: 36064084
Cancer Res. 2012 Sep 1;72(17):4294-9
pubmed: 22915758
Nanomedicine. 2014 Jan;10(1):99-107
pubmed: 23891983
Drug Dev Ind Pharm. 2018 Feb;44(2):306-315
pubmed: 29023168
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8634-9
pubmed: 16731632
Int J Pharm. 2018 Jul 30;546(1-2):215-225
pubmed: 29787895
J Nanobiotechnology. 2022 Jul 2;20(1):222
pubmed: 35778747
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
J Control Release. 2013 Nov 10;171(3):349-57
pubmed: 23648833
Front Bioeng Biotechnol. 2022 Aug 05;10:949704
pubmed: 35992340
Nat Med. 2012 Sep;18(9):1332-4
pubmed: 22961158
Pharm Res. 2017 Nov;34(11):2371-2384
pubmed: 28875330
Drug Resist Updat. 2019 Sep;46:100645
pubmed: 31585396
J Exp Clin Cancer Res. 2018 May 29;37(1):110
pubmed: 29843754
Front Pharmacol. 2019 Jul 26;10:820
pubmed: 31402861
Mol Cancer. 2017 Jul 28;16(1):134
pubmed: 28754120
Nanomaterials (Basel). 2019 May 31;9(6):
pubmed: 31159219
Sci Rep. 2016 Mar 31;6:23859
pubmed: 27030638
J Mater Chem B. 2020 Nov 4;8(42):9621-9641
pubmed: 32955058
Nano Lett. 2018 Jun 13;18(6):3814-3822
pubmed: 29694050
Int J Pharm. 2012 Apr 4;425(1-2):62-72
pubmed: 22266532
Adv Sci (Weinh). 2021 May 16;8(14):2100540
pubmed: 34306980
J Natl Cancer Inst. 2022 Jun 13;114(6):907-909
pubmed: 34181001
Acta Biomater. 2021 Nov;135:556-566
pubmed: 34496281
Ther Deliv. 2015 Jan;6(1):41-58
pubmed: 25565440
Cancer Treat Rev. 2008 Nov;34(7):592-602
pubmed: 18538481
Life Sci. 2019 Sep 1;232:116636
pubmed: 31295471
Langmuir. 2018 Jul 24;34(29):8685-8693
pubmed: 29932659
J Control Release. 2021 Mar 10;331:335-349
pubmed: 33484779
Biomedicines. 2022 Jan 26;10(2):
pubmed: 35203492
Biotechnol Lett. 2021 May;43(5):981-994
pubmed: 33515341
Polymers (Basel). 2021 Jul 27;13(15):
pubmed: 34372067